Last reviewed · How we verify

NCT04210609: VHTDFU2

Effectiveness of Vaporous Hyperoxia Therapy (VHT) in the Treatment of Chronic Diabetic Foot Ulcers

Status unknown NA Last updated 11 October 2021
What this trial tests

NA trial testing Vaporous Hyperoxia Therapy in Diabetic Foot Ulcer in 30 participants. Status unknown.

Timeline
4 October 2021
Primary endpoint
3 October 2022
3 October 2022

Quick facts

Lead sponsorVaporox
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date4 October 2021
Primary completion3 October 2022
Estimated completion3 October 2022
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vaporox

Who can join

Adults 18 to 75, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effectiveness of Vaporous Hyperoxia Therapy (VHT) for the treatment of Diabetic Foot Ulcers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vaporous Hyperoxia Therapy

Trials testing the same drug.

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

Other Vaporox trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing